Spotlight on ceritinib in the treatment of ALK+ NSCLC: design, development and place in therapy

The identification of echinoderm microtubule-associated protein-like 4 (EML4) and anaplastic lymphoma kinase (ALK) fusion gene in non-small cell lung cancer (NSCLC) has radically changed the treatment of a subset of patients harboring this oncogenic driver. Crizotinib was the first ALK tyrosine kina...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Drug Des Devel Ther
Main Authors: Santarpia, Mariacarmela, Daffinà, Maria Grazia, D’Aveni, Alessandro, Marabello, Grazia, Liguori, Alessia, Giovannetti, Elisa, Karachaliou, Niki, Gonzalez Cao, Maria, Rosell, Rafael, Altavilla, Giuseppe
Format: Artigo
Jezik:Inglês
Izdano: Dove Medical Press 2017
Teme:
Review
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC5503498/
https://ncbi.nlm.nih.gov/pubmed/28740365
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/DDDT.S113500
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki